IBJNews

Lilly's Alzheimer's drug trials show mixed results

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.

The Indianapolis-based drugmaker announced the mixed clinical trial results Friday morning. The drug, called solanezumab, was studied in a total of more than 2,000 patients with mild or moderate Alzheimer’s disease.

The drugmaker's stock rose 7.5 percent  in premarket trading.

Lilly’s analysis of the data after the trial showed that solanezumab slowed cognitive decline in mild Alzheimer’s patients but not in moderate ones.

The finding, in a subgroup of patients, wasn’t expected by analysts and investors, who had given the drug a less than 20 percent chance of showing any benefit.

That finding is a first for any drug trying to combat the memory-sapping malady, which afflicts 5 million Americans and 18 million people worldwide. Lilly is trying to make solanezumab the first drug to successfully fight the progress of Alzheiemr’s disease, which, if successful, is almost certain to generate billions of dollars per year in sales.

A similar-acting medicine from Pfizer Inc. and Johnson & Johnson failed to show a benefit earlier this month. If approved for a wide population of Alzheimer’s sufferers, the treatment may “transform” Lilly and bring in $5 billion to $10 billion in annual sales, said Goldman Sachs analyst Jami Rubin in a note to clients last month. That would be much needed revenue for Lilly as it braces to lose $7 billion from generic competition over the next five years.

"We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline," said Lilly CEO John Lechleiter in a prepared statement. "We intend to discuss these data with regulatory authorities to gain their insights on potential next steps."

That could include another clinical trial of solanezumab aimed at patients with who have yet to develop full-blown Alzheimer’s symptoms. That’s because recent research has shown that that suspected causes of Alzheimer’s disease begin 10 or even 20 years before a patient can be diagnosed with the disease.

Lilly’s drug solanezumab fights Alzheimer’s by trying to remove a protein called amyloid beta from patients’ brains. The build-up amyloid into clumps and plaques is believed by many to stop the functioning of neurons, leading to memory loss and eventually death.

The only other therapy in late-stage testing is Baxter International Inc.’s Gammagard. The product is an expensive, relatively scarce treatment derived from donated blood plasma that replaces antibodies in people whose immune systems can’t protect them from infection. Results from a final-stage study on whether it could slow or stop Alzheimer’s may be available next year.

Lilly lost patent protection last year on its top-seller Zyprexa for schizophrenia and will lose the patent next year for its second-best seller, the anti-depressant Cymbalta. The drugs combined for 36 percent of Lilly’s 2011 revenue.

Lechleiter has said the company’s annual revenue will not be less than $20 billion and profit will remain more than $3 billion through 2014. In 2011, Lilly brought in revenue of $24.3 billion with a profit of $4.35 billion.

Lilly has 11 other medicines in late-stage testing, six of which may generate more than $1 billion each in peak annual sales, said Jeffrey Holford, an analyst with Jefferies Group Inc. in New York. Sales from those drugs won’t come soon enough to overcome the losses Lilly faces through at least 2017, he said.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So as I read this the one question that continues to come to me to ask is. Didn't Indiana only have a couple of exchanges for people to opt into which were very high because we really didn't want to expect the plan. So was this study done during that time and if so then I can understand these numbers. I also understand that we have now opened up for more options for hoosiers to choose from. Please correct if I'm wrong and if I'm not why was this not part of the story so that true overview could be taken away and not just parts of it to continue this negative tone against the ACA. I look forward to the clarity.

  2. It's really very simple. All forms of transportation are subsidized. All of them. Your tax money already goes toward every single form of transportation in the state. It is not a bad thing to put tax money toward mass transit. The state spends over 1,000,000,000 (yes billion) on roadway expansions and maintenance every single year. If you want to cry foul over anything cry foul over the overbuilding of highways which only serve people who can afford their own automobile.

  3. So instead of subsidizing a project with a market-driven scope, you suggest we subsidize a project that is way out of line with anything that can be economically sustainable just so we can have a better-looking skyline?

  4. Downtowner, if Cummins isn't getting expedited permitting and tax breaks to "do what they do", then I'd be happy with letting the market decide. But that isn't the case, is it?

  5. Patty, this commuter line provides a way for workers (willing to work lower wages) to get from Marion county to Hamilton county. These people are running your restaurants, hotels, hospitals, and retail stores. I don't see a lot of residents of Carmel working these jobs.

ADVERTISEMENT